Lousada I, et al. Light chain amyloidosis: Patient experience survey from the Amyloidosis Research Consortium. Adv Ther 2015; 32:920–928. doi: 10.1007/s12325-015-0250-0

• PubMed
Lousada I, Light chain amyloidosis: Patient experience survey from the Amyloidosis Research Consortium. Adv Ther 2015; 32:920–928. doi: 10.1007/s12325-015-0250-0 )| false
• Search Google Scholar
• Export Citation

Dispenzieri A, et al. Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. Blood 2004; 104:1881–1887. doi: 10.1182/blood-2004-01-0390

• PubMed
Dispenzieri A, Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. Blood 2004; 104:1881–1887. doi: 10.1182/blood-2004-01-0390 )| false
• Search Google Scholar
• Export Citation

Palladini G, et al. A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis. Blood 2014; 124:2325–2332. doi: 10.1182/blood-2014-04-570010

• PubMed
Palladini G, A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis. Blood 2014; 124:2325–2332. doi: 10.1182/blood-2014-04-570010 )| false
• Search Google Scholar
• Export Citation

Venner CP, et al. Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival. Blood 2012; 119:4387–4390. doi: 10.1182/blood-2011-10-388462

• PubMed
Venner CP, Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival. Blood 2012; 119:4387–4390. doi: 10.1182/blood-2011-10-388462 )| false
• Search Google Scholar
• Export Citation

Mikhael JR, et al. Cyclophosphamide-bortezomibdexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis. Blood 2012; 119:4391–4394. doi: 10.1182/blood-2011-11-390930

• PubMed
Mikhael JR, Cyclophosphamide-bortezomibdexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis. Blood 2012; 119:4391–4394. doi: 10.1182/blood-2011-11-390930 )| false
• Search Google Scholar
• Export Citation

Palladini G, et al. A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis. Blood 2015; 126:612–615. doi: 10.1182/blood-2015-01-620302

• PubMed
Palladini G, A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis. Blood 2015; 126:612–615. doi: 10.1182/blood-2015-01-620302 )| false
• Search Google Scholar
• Export Citation

Kaufman GP, et al. Daratumumab yields rapid and deep hematologic responses in patients with heavily pretreated AL amyloidosis. Blood 2017; 130:900–902. doi: 10.1182/blood-2017-01-763599

• PubMed
Kaufman GP, Daratumumab yields rapid and deep hematologic responses in patients with heavily pretreated AL amyloidosis. Blood 2017; 130:900–902. doi: 10.1182/blood-2017-01-763599 )| false
• Search Google Scholar
• Export Citation

Sanchorawala V, et al. Safety, tolerability, and response rates of daratumumab in relapsed AL amyloidosis: Results of a phase 2 study. Blood 2020; 135:1541–1547. doi: 10.1182/blood.2019004436

• PubMed
Sanchorawala V, Safety, tolerability, and response rates of daratumumab in relapsed AL amyloidosis: Results of a phase 2 study. Blood 2020; 135:1541–1547. doi: 10.1182/blood.2019004436 )| false
• Search Google Scholar
• Export Citation

Kastritis E, et al. Daratumumab-based treatment for immunoglobulin light-chain amyloidosis. N Engl J Med 2021; 385:46–58. doi: 10.1056/NEJMoa2028631

• PubMed
Kastritis E, Daratumumab-based treatment for immunoglobulin light-chain amyloidosis. N Engl J Med 2021; 385:46–58. doi: 10.1056/NEJMoa2028631 )| false
• Search Google Scholar
• Export Citation

Palladini G, et al. Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: Safety run-in results of ANDROMEDA. Blood 2020; 136:71–80. doi: 10.1182/blood.2019004460

• PubMed
Palladini G, Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: Safety run-in results of ANDROMEDA. Blood 2020; 136:71–80. doi: 10.1182/blood.2019004460 )| false
• Search Google Scholar
• Export Citation

Landau H, et al. Long-term event-free and overall survival after risk-adapted melphalan and SCT for systemic light chain amyloidosis. Leukemia 2017; 31:136–142. doi: 10.1038/leu.2016.229

• PubMed
Landau H, Long-term event-free and overall survival after risk-adapted melphalan and SCT for systemic light chain amyloidosis. Leukemia 2017; 31:136–142. doi: 10.1038/leu.2016.229 )| false
• Search Google Scholar
• Export Citation